Literature DB >> 2684616

Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.

S Suzuki1, K Kawai, S Ohashi, H Mukai, K Yamashita.   

Abstract

Truncated glucagon-like peptide-1 (GLP-1) possesses a potent stimulatory activity for insulin secretion and a slight inhibiting activity for glucagon secretion. The aim of this paper is to examine the activities of N- and C-terminal fragments of GLP-1 using a rat pancreas perfusion system. Concerning the N-terminal portion, GLP-1(7-37) amide elicited a clear insulinotropic activity at 0.1 or 1 nM with the perfusate containing 5.5 mM glucose and 5 mM arginine, while 10 nM GLP-1-(1-37) amide, -(6-37) amide, and -(8-37) amide did not. Concerning the C-terminal portion, GLP-1-(7-37) amide, -(7-37), and -(7-36) amide had a similar potency of insulinotropic activity, and GLP-1-(7-35) was less potent; 0.1 nM GLP-1-(7-35) did not stimulate insulin release, nor did 10 nM GLP-1-(7-20). Glucagon release was significantly suppressed by 1 and 10 nM GLP-1-(7-37) amide, 10 nM GLP-1-(7-37), and 1 nM GLP-1-(7-36) amide. Other fragment peptides of GLP-1, including GLP-1-(7-35), had no effect. From these results it is concluded that histidine at position 7 of GLP-1 as a free N-terminal amino acid is very important in GLP-1's insulinotropic activity and probably in glucagon-inhibiting activity, and that C-terminal amidation and three C-terminal amino acids are less important for these activities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684616     DOI: 10.1210/endo-125-6-3109

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

1.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release.

Authors:  P L Brubaker; S Efendic; G R Greenberg
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

Review 2.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Metabolic and endocrine functions of glucagon-like peptides - evolutionary and biochemical perspectives.

Authors:  T P Mommsen; E M Plisetskaya
Journal:  Fish Physiol Biochem       Date:  1993-07       Impact factor: 2.794

4.  Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide.

Authors:  W E Schmidt; H Kratzin; K Eckart; D Drevs; G Mundkowski; A Clemens; S Katsoulis; H Schäfer; B Gallwitz; W Creutzfeldt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

Review 5.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 6.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

7.  Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms.

Authors:  J Gromada; S Dissing; P Rorsman
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

8.  Systemic delivery of bioactive glucagon-like peptide 1 after adenoviral-mediated gene transfer in the murine salivary gland.

Authors:  Antonis Voutetakis; Ana P Cotrim; Anne Rowzee; Changyu Zheng; Trushar Rathod; Tulin Yanik; Y Peng Loh; Bruce J Baum; Niamh X Cawley
Journal:  Endocrinology       Date:  2010-07-07       Impact factor: 4.736

9.  C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor.

Authors:  Andrew C Emery; Ryan A Alvarez; Philip Abboud; Wenqin Xu; Craig D Westover; Maribeth V Eiden; Lee E Eiden
Journal:  Peptides       Date:  2016-03-11       Impact factor: 3.750

Review 10.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.